Kamada Ltd (KMDA) Q4 2025 Earnings Call Transcript

Why It Matters

The results underscore Kamada’s expanding product portfolio and diversified revenue streams, positioning the firm for sustained profitable growth in the plasma‑derived therapeutics market.

Key Takeaways

• Q3 revenue up 13% to $47 million.
• Adjusted EBITDA rose 34% to $11.7 million.
• Full‑year revenue guidance remains $178‑$182 million.
• KedRAB supply secured through 2031 minimum order commitments.
• Texas plasma centers to generate $8‑$10 million each.

Pulse Analysis

Kamada’s latest earnings highlight a strategic shift toward a more balanced, geography‑diverse revenue mix. While its flagship anti‑rabies product KedRAB continues to dominate the U.S. market, growth is increasingly driven by ex‑U.S. sales of GALASIA and an expanding distribution segment that now includes biosimilar launches. The company’s ability to sustain double‑digit top‑line growth despite a modest royalty decline on Glacia demonstrates the resilience of its commercial model and the effectiveness of its four‑pillar strategy.

The pipeline remains a key catalyst for future upside. The SHIELD study, the first controlled trial of Cytogam in high‑risk kidney transplant recipients, aims to broaden the product’s indication and could unlock new market share in the CMV space. Simultaneously, the Phase III INNOVATE inhaled AAT trial is progressing toward an interim futility analysis, with top‑line data expected in 2029, positioning Kamada to address an unmet need in alpha‑1 antitrypsin deficiency. Biosimilar introductions are projected to contribute $2.5 million this year and scale to $15‑$20 million annually within five years, reinforcing the distribution business’s growth trajectory.

Operationally, Kamada is strengthening its supply chain through the recent FDA approval of its Houston plasma center and the upcoming San Antonio facility, each projected to generate $8‑$10 million at full capacity. Coupled with a firm minimum‑order commitment for KedRAB through 2031 and active M&A diligence targeting complementary assets, the company is building a vertically integrated platform that mitigates sourcing risk and fuels long‑term cash generation. With $72 million in cash and robust operating cash flow, Kamada is well‑positioned to fund its strategic initiatives and deliver shareholder value in a competitive biologics landscape.